Author

R. K. R. Rajoli

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. Owen· 3 shared A. C. Ferreira· 2 shared A. d. P. D. Da Silva· 2 shared C. Q. Sacramento· 2 shared D. C. Bou-Habib· 2 shared J. R. Temerozo· 2 shared M. Mattos· 2 shared N. Fintelman-Rodrigues· 2 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

A. Owen

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

MicrobiologybioRxivJul 21, 2021

Unlike Chloroquine, mefloquine inhibits SARS-CoV-2 infection in physiologically relevant cells and does not induce viral variants.

C. Q. Sacramento, N. Fintelman-Rodrigues, S. S. G. Dias…·T. M. L. Souza

This paper shows mefloquine inhibits SARS-CoV-2 infection in relevant cells more effectively than chloroquine without promoting viral mutations.

DOI 10.3390/v14020374

humanbulk RNA-seq

𝕏 PostBluesky

Pharmacology & ToxicologybioRxivPreprintFeb 3, 2021

Development of a highly sensitive bioanalytical assay for the quantification of favipiravir.

P. Curley, M. Neary, U. Arshad…·A. Owen

This paper develops a sensitive LC-MS/MS assay for quantifying favipiravir, showing high accuracy and precision across a wide concentration range.

DOI 10.1101/2021.02.03.429628

experimental assaydrug response / drug discovery

𝕏 PostBluesky

MicrobiologybioRxivPreprintJun 15, 2020

The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2

C. Q. Sacramento, N. Fintelman-Rodrigues, J. R. Temerozo…·T. M. L. Souza

This study evaluates the antiviral activity of daclatasvir and sofosbuvir against SARS-CoV-2 in vitro, showing inhibition of viral replication and associated pathologies.

DOI 10.1101/2020.06.15.153411

humanexperimental assay

𝕏 PostBluesky